RSLB.F Stock Overview
A medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
RaySearch Laboratories AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 22.50 |
| 52 Week High | SEK 26.74 |
| 52 Week Low | SEK 12.40 |
| Beta | 1.15 |
| 1 Month Change | -1.36% |
| 3 Month Change | 9.22% |
| 1 Year Change | n/a |
| 3 Year Change | 394.51% |
| 5 Year Change | 291.30% |
| Change since IPO | 922.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| RSLB.F | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | -1.7% |
| 1Y | n/a | 1.5% | 3.6% |
Return vs Industry: Insufficient data to determine how RSLB.F performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how RSLB.F performed against the US Market.
Price Volatility
| RSLB.F volatility | |
|---|---|
| RSLB.F Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 11.9% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: RSLB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RSLB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 416 | Johan Lof | www.raysearchlabs.com |
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. It develops and markets RayStation, a treatment planning system for radiation therapy; RayCare, an oncology information system that manages clinical activities; RayIntelligence, a cloud-based analytics system for monitoring and enhancement of cancer therapy; and RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems. The company offers RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, and electron beam radiation therapy; and µ-RayStation, a software platform for planning and evaluation in small animal irradiation research.
RaySearch Laboratories AB (publ) Fundamentals Summary
| RSLB.F fundamental statistics | |
|---|---|
| Market cap | US$870.54m |
| Earnings (TTM) | US$21.23m |
| Revenue (TTM) | US$124.35m |
41.0x
P/E Ratio7.0x
P/S RatioIs RSLB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RSLB.F income statement (TTM) | |
|---|---|
| Revenue | SEK 1.19b |
| Cost of Revenue | SEK 99.49m |
| Gross Profit | SEK 1.09b |
| Other Expenses | SEK 889.02m |
| Earnings | SEK 203.51m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 25, 2025
| Earnings per share (EPS) | 5.61 |
| Gross Margin | 91.65% |
| Net Profit Margin | 17.07% |
| Debt/Equity Ratio | 0% |
How did RSLB.F perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield51%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/23 19:47 |
| End of Day Share Price | 2025/03/26 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RaySearch Laboratories AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Hans Mähler | DNB Markets |
| Hans Mähler | Handelsbanken Capital Markets |